Form 4: Tandem Diabetes Care Executive Reports Stock Transactions
SEC Form 4 Filing
Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 15, 2024, Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care, had 405 shares of common stock acquired through the vesting of restricted stock units (RSUs).
- Also on March 15, 2024, 145 shares were withheld by Tandem Diabetes Care to satisfy tax obligations related to the vesting of these RSUs at a price of $28.62 per share.
- Following these transactions, Carpenter directly owns 6,100 shares of Tandem Diabetes Care common stock and 2,842 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages including stock options and RSUs are standard practice in the medical device industry.
- Companies like Insulet and Dexcom also utilize similar equity-based compensation to align executive interests with shareholder value.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects standard executive compensation practices.
- Employees may be interested in the details of executive compensation as a benchmark.
Key Dates
| Date | Description |
|---|---|
| 12/15/2021 | Date of RSU award. |
| 12/15/2022 | First vesting date of the RSU award (25%). |
| 03/15/2024 | Date of stock acquisition and tax withholding. |
| 03/19/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.